SUZHOU, China, Sept. 14, 2023 /PRNewswire/ -- On September 13th, 2023, Porton Advanced Solutions (Porton Advanced) announced a strategic partnership with BRL Medicine Inc. (BRL Medicine). This collaboration will enhance the cell and gene therapy pipelines from BRL Medicine from clinical trials to further expedite the commercialization of innovative therapies.
Porton Advanced Solutions and DanausGT Biotechnology announced on February 27, 2023, a cell and gene therapy collaboration to expedite the development of innovative therapeutics.
SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd. (Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on February 27, 2023, a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics.
Porton Advanced and Yinjia Biosciences Partner to Enhance CDMO Technology Platform
Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services
SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- On August 19, 2022, Porton Advanced Solutions. (hereinafter referred to as Porton Advanced) announced a strategic cooperation with Suzhou Royaltech Med Co., Ltd. (hereinafter referred to as Suzhou Royaltech). This strategic collaboration will further integrate the resources and capabilities of both parties, jointly promote the establishment of microbial vectors used for gene therapy (MVGTs) ( listeria monocytogenes) and mRNA drug platform technology, and accelerate the R&D process of bioinnovative drugs.
Porton Advanced Solutions has raised $80m in a Series B funding round to expand its end-to-end gene and cell therapy (GCT) contract development and manufacturing organisation (CDMO) platforms.
Porton Advanced Solutions completes a Series B financing round to expand its end-to-end Gene and Cell Therapy CDMO Platforms